Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Energy And Commerce Committee Chair Upton Is Orphan Drug Advocate

This article was originally published in The Pink Sheet Daily

Executive Summary

Newly-selected House Energy and Commerce Committee Chairman Fred Upton, R-Mich., brings a commitment to orphan drug development to his new role.

You may also be interested in...



"Dormant" Drug Candidates Eligible For Exclusivity Incentives In Draft Bill

Bill floated by the National Health Council would promote development of therapies that have the potential to address an unmet medical need but are viewed by the biopharma industry as unattractive candidates because they have insufficient patent protection.

“Dormant” Drug Candidates Eligible For Exclusivity Incentives In Draft Bill

Biopharmaceutical companies would be offered data exclusivity incentives to develop “dormant” drug candidates for unmet medical needs under draft legislation being floated in the House by the National Health Council patient advocacy organization.

"Dormant" Drug Candidates Eligible For Exclusivity Incentives In Draft Bill

Bill floated by the National Health Council would promote development of therapies that have the potential to address an unmet medical need but are viewed by the biopharma industry as unattractive candidates because they have insufficient patent protection.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel